Condition Guide

Peptides for Chronic Viral Hepatitis

Thymosin Alpha-1 (brand Zadaxin) is approved in over 30 countries as an adjunctive therapy for chronic hepatitis B and C, typically combined with interferon or direct-acting antivirals.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

How peptides help

Thymosin Alpha-1 enhances dendritic cell maturation and T-cell response, improving viral clearance rates when added to standard therapy.

Peptides researched for chronic viral hepatitis

Thymosin Alpha-1

Strong EvidenceL4

Approved in 30+ countries; not FDA.

113 studies · Dendritic Cell & T-Cell Activation

State of the evidence

Multiple international Phase III trials support adjunctive use. Not FDA approved in the U.S.

Frequently asked

Does Thymosin Alpha-1 cure hepatitis C?

It is used adjunctively to improve the response to antiviral therapy, not as monotherapy. Modern direct-acting antivirals (DAAs) have high cure rates on their own.

Related conditions

Immune Dysfunction

Thymic peptides that restore T-cell and dendritic-cell function.